NCT04231214View on ClinicalTrials.gov

Effects of Spiolto® Respimat® (Tiotropium/Olodaterol) on Cardiac Function in Hyperinflated COPD Subjects

PHASE4CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

January 28, 2020

Primary Completion Date

April 18, 2023

Study Completion Date

April 18, 2023

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Olodaterol-Tiotropium

5µg Olodaterol and 5 µg Tiotropium via the soft mist inhaler Respimat®, administered once on Day 1 or Day 9 and daily from Day 10 to Day 24

Trial Locations (1)

30625

Fraunhofer ITEM, Hanover

Sponsors

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

Fraunhofer-Institute of Toxicology and Experimental Medicine

OTHER